The global oligonucleotide CDMO market, valued at USD 911.78 million in 2024, is projected to skyrocket to USD 3,168.97 million by 2033, surging at a robust compound annual growth rate (CAGR) of 14.98% from 2025 to 2033, according to the latest Grand View Research report. This remarkable expansion is fueled by the booming clinical pipelines of antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), alongside the widening adoption of mRNA therapeutics far beyond vaccines, as biotech innovators increasingly outsource intricate manufacturing to specialized Contract Development and Manufacturing Organizations (CDMO) to bypass capacity bottlenecks and ensure GMP-compliant scalability. North America commands a dominant 36.02% revenue share in 2024, powered by cutting-edge R&D ecosystems and trailblazing firms, while Asia Pacific emerges as the fastest-growing region thanks to cost efficiencies and surging clinical trials.
Surging Demand Drives CDMO Outsourcing Boom
Contract manufacturing leads with a 63.78% market share in 2024, as pharmaceutical giants and emerging biotechs demand large-scale production for late-stage trials and commercial launches of oligo-based drugs targeting oncology, rare genetic disorders, and neuromuscular conditions like ALS. The therapeutic application segment reigns supreme, bolstered by FDA approvals for precision therapies such as Qalsody, while advancements in solid-phase synthesis, impurity control, and conjugation technologies like GalNAc and LNPs address key delivery hurdles. Pharmaceutical and biopharmaceutical end-users dominate outsourcing decisions to streamline costs, mitigate risks, and accelerate time-to-market amid a pipeline swollen with over 100 oligo candidates in active development.
Market Segments in Depth
The Oligonucleotide CDMO market, exhibits nuanced segmentation that underscores its alignment with therapeutic innovation and outsourcing demands. By service, contract manufacturing dominates with a commanding 63.78% revenue share in 2024, driven by the critical need for scalable GMP-compliant production to support clinical trials and commercial launches of complex oligonucleotides, while contract development services emerge as the fastest-growing segment due to escalating requirements for process optimization, impurity profiling, and analytical method validation in early-to-mid-stage pipelines. In terms of type, antisense oligonucleotides (ASOs) lead the pack, propelled by extensive clinical pipelines targeting rare genetic diseases, neurological disorders like ALS, and metabolic conditions, whereas small interfering RNAs (siRNAs) register the highest growth trajectory amid surging oncology applications and enhanced delivery technologies such as lipid nanoparticles (LNPs). The application landscape is topped by therapeutics, which capture the lion's share through oligo-based drugs addressing chronic illnesses, cancer, and gene silencing therapies including FDA-approved breakthroughs like Qalsody, followed by robust growth in research for target validation and diagnostics fueled by PCR probes and genetic testing proliferation. End-use segmentation highlights pharmaceutical and biopharmaceutical companies as the frontrunners, outsourcing to circumvent in-house capacity constraints and regulatory hurdles, with contract research organizations (CROs), academic institutes, and diagnostic labs gaining momentum as personalized medicine expands. Regionally, North America holds a 36.02% share in 2024, bolstered by biotech hubs and stringent FDA oversight, while Asia Pacific accelerates as the fastest-growing area leveraging manufacturing cost advantages in India and China alongside rising clinical trial activity. These segments collectively illustrate a market poised for targeted expansion, with therapeutic ASOs in contract manufacturing representing the epicenter of value creation.
Spotlight on Industry Trailblazers
Leading CDMOs are aggressively expanding capacities to capture this gold rush. PolyPeptide Group, with cGMP facilities across Europe, the U.S., and India, excels in peptide-oligo hybrids for metabolic and cancer therapies, supporting clients from preclinical to blockbuster scales. STA Pharmaceutical Co. Ltd., a WuXi AppTec powerhouse in China, leverages Asia's cost advantages for high-volume siRNA and ASO production, fueling global oncology pipelines. Bachem Holding AG delivers ultra-pure GMP oligos from Swiss and U.S. sites, powering FDA-approved ASOs for neurological disorders with unmatched process expertise.
Recent Developments
In July 2024, CordenPharma announced to invest USD 1061.24 million (Euro 900 Million), which aims to expand its peptide platform, both at its Colorado, U.S. site and in Europe. This expansion covers both existing facilities and new constructions.
In April 2024, Aurigene Pharmaceutical Services Ltd. Entered into a partnership agreement with Vipergen ApS, a small-molecule drug discovery service provider, which aims to accelerate innovation in drug discovery by increasing success rates and reducing timelines through screening a more billion small-molecule compounds.
A New Era for Precision Medicine
As oligonucleotide therapies redefine treatment paradigms from silencing defective genes to editing disease pathways, the CDMO market emerges as the indispensable backbone, promising faster innovation, reliable supply chains, and broader access to life-changing drugs worldwide. Industry leaders partnering with these agile CDMOs today will lead tomorrow's genomic revolution, capitalizing on a market poised to triple in value by 2033.
For the full Grand View Research report and deeper insights, visit Oligonucleotide CDMO Market Report
#OligonucleotideCDMO #OligoCDMO #OligonucleotideSynthesis #Biotech #Biopharma #LifeSciences #Pharma #CDMO #SyntheticBiology #RNASynthesis #PrecisionMedicine #GeneTherapy #Biotechnology #PharmaManufacturing #DrugDevelopment #MarketTrends
Sign in to leave a comment.